ZWS Stock Forecast & Price Target

Zurn Elkay Water Solns is supported by a defensively skewed, specification-driven portfolio tied heavily to education and healthcare, which together represent 80% of institutional sales and help stabilize demand through weaker construction cycles. The company is also demonstrating strong operating leverage, with 3Q26 organic sales up 7%, adjusted EBITDA margin at 28.3%, incremental margins of 45%, and raised 2026 adjusted EBITDA guidance to $512-$515 million alongside free cash flow above $350 million. Its outlook is further strengthened by 0.4x net leverage, $307 million of cash, $135 million of year-to-date buybacks, an 18% dividend increase, and roughly $400 million of served-market expansion from adjacencies like Intellihot and digital mixing valves.

Zurn Elkay Water Solns is facing a softer near-term demand outlook, as management cut 4Q26 organic growth expectations from mid-single digits to an implied 3%-5% amid macro uncertainty, with slower nonresidential construction and deferred institutional budgets weighing on education and healthcare demand. The stock also looks vulnerable to downside if institutional and commercial remodel activity slows materially, since sustained below-market growth or share loss could compress its premium versus peers and translate into materially worse performance. On top of that, its elevated P/E multiple already reflects strong positioning, while execution risks around M&A, commodity inflation, supply chain disruptions, and slower adoption of touchless or IoT products could pressure margins and growth.